MetaCap

Aquestive Therapeutics (AQST) vs Evolus (EOLS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Evolus (EOLS) has outperformed Aquestive Therapeutics (AQST) over the past year, losing 4.8% versus a loss of 39.5%. Over five years, EOLS leads with a +14.4% price change compared with -45.7% for AQST. Aquestive Therapeutics is the larger company by market cap ($434.9 million vs $431.5 million), about 1.0 times the size, while Evolus is growing revenue faster (+11.6% vs -22.6%).

Evolus converts more of its revenue into profit, with a net margin of -17.4% versus -188.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AQST-39.51%EOLS-4.82%
+40%-6%-53%
Nov 21, 20251 yearNov 20, 2026
AQST-42.04%EOLS+2.19%
+187%+42%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AQST versus EOLS key metrics
MetricAQSTEOLS
Share price$3.46$6.52
Market cap$434.88M$431.55M
1-day change-6.61%-6.86%
YTD return-46.44%-1.95%
1-year return-39.51%-4.82%
5-year return-45.68%+14.39%
Forward P/E—22.68
EPS (TTM)$-0.65$-0.48
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$44.55M$297.18M
Revenue growth (YoY)-22.61%+11.61%
Net income (latest FY)$-83.78M$-51.64M
Gross margin58.35%66.33%
Operating margin-159.50%-10.99%
Net margin-188.09%-17.38%
52-week high$6.74$9.31
52-week low$2.93$3.86
Distance from 52-week high-48.63%-29.97%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+169.65%+136.20%
Average volume2.41M925.77K
Shares outstanding125.69M66.19M
Employees147365
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EOLS has outperformed AQST by 34.7 percentage points over the past year.
  • Evolus is more profitable, keeping -17.4 cents of every revenue dollar as net income versus -188.1 cents for Aquestive Therapeutics.
  • Evolus grew revenue faster in its latest fiscal year (+11.61% vs -22.61%).

About Aquestive Therapeutics

AQST stock →

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees

About Evolus

EOLS stock →

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.

Health Care · Biotechnology: Pharmaceutical Preparations · 365 employees

AQST vs EOLS FAQ

Which is bigger, Aquestive Therapeutics or Evolus?

Aquestive Therapeutics (AQST) is larger, with a market capitalization of $434.88M compared with $431.55M for Evolus (EOLS).

Which stock has performed better over the past year, AQST or EOLS?

EOLS returned -4.82% over the past 12 months, compared with -39.51% for AQST (price return, excluding dividends). Past performance does not predict future results.

Are Aquestive Therapeutics and Evolus in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons